Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617

Brain metastases are not common in prostate cancer; they typically occur in patients with end-stage disease who are castrate-resistant. Patients with brain metastases have very limited survival. Traditionally, the mainstays of therapy have been surgical resection, chemotherapy and external beam radiotherapy. Recently, combination of 177Lu-Prostatespecific membrane antigen (PSMA)-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer (mCRPC) showed significant regression in the sizes and PSMA-ligand avidity of the lesions over time. Recent studies have demonstrated that targeted α-radiation therapy with 225Ac-PSMAligand can significantly benefit patients with mCRPC in the appropriate setting. Targeted α-radiation therapy may be more effective for the treatment of mCRPC, and has been shown, in limited number of patients, to be effective in the setting of resistant to 177Lu-PSMA-617 therapy.

SATHEKGE Mike;  BRUCHERTSEIFER Frank;  LAWAL I;  VORSTER Mariza;  KNOESEN Otto;  LENGANA T;  BOSHOMANE T;  MOKOALA K;  MORGENSTERN Alfred; 

2019-07-24

SPRINGER

JRC116617

1619-7070 (online),   

https://publications.jrc.ec.europa.eu/repository/handle/JRC116617,   

10.1007/s00259-019-04354-z (online),